colon and rectal (colorectal) cancer

Vanderbilt's Andreana Holowatyj, PhD, MSCI, has received the National Cancer Institute’s Method to Extend Research in Time Award to support her ongoing investigation into how early-onset colorectal cancer and its treatments impact reproductive health.

An antioxidant transporter of the trace mineral selenium that protects against inflammatory bowel disease has the opposite effect in colorectal cancer, where it promotes tumor growth, researchers at Vanderbilt University Medical Center have reported.

Research conducted at Vanderbilt points to a new therapy is on the horizon for patients with metastatic colorectal cancer who have run out of treatment options.

A Vanderbilt study that delved into genetic predisposition for early-onset colorectal cancer by race and ethnicity has identified differing germline risk variants.

Fluorescent nanoparticles clearly identified colonic adenomas — precursors to colorectal cancer — in mice, and the formulation should translate to clinical use in humans.

Vanderbilt researchers are studying precancerous lesions and early cancers in the colon, with the goal of developing new ways to prevent colorectal cancer, the nation’s second leading cancer killer.

Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.